Clinical Trials Directory

Trials / Unknown

UnknownNCT05753332

Association Between PM2.5 and Ferroptosis

Association Between Short-term PM2.5 Exposures and Nrf2 Dependent Ferroptosis Pathway

Status
Unknown
Phase
Study type
Observational
Enrollment
60 (actual)
Sponsor
Northern Jiangsu People's Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This cohort study aims to discover the possible effects of PM2.5 exposures on the Nrf2- dependent ferroptosis pathway. This observational cohort's main question is whether PM2.5 exposures will affect the Nrf2- dependent ferroptosis pathway. Participants will be divided into two groups: the control group and the air pollution to detect the biomarkers of the Nrf2- dependent ferroptosis pathway.

Detailed description

Background: Despite the exact mechanism of the effects of air pollution (PM2.5) on the central nervous system is still under debate, there is increasing evidence that air pollution (PM2.5) will cause cognitive decline. It is well known that air pollution (PM2.5) will cause the release of proinflammatory cytokines by microglia and cognitive decline. TNF-α plays a key role in cognitive function and our previous research indicated that Nrf2 plays a crucial role in seizures-induced cognitive function (NCT05269901) . However, whether PM2.5-induced TNF-α will further trigger Nrf2- dependent ferroptosis to facilitate cognitive decline is still unexplored. This pilot clinical trial aims to discover the possible association between PM2.5 exposures and the changes in TNF-α level and Nrf2- dependent ferroptosis pathway. Methods: 1. The investigators first analyze the genes expression of the GSE60767 from the GEO database (www.ncbi.nlm.nih.gov/geo) using the GPL6947 platform 2. The investigators enrolled 30 people and aged-matched PM2.5 exposures people from two cities (Yangzhou and Xuzhou) as the control and air pollution group based on previous PM2.5 records; 3. Recorded the PM2.5 level in two cities every 5 days between 2022.12 and 2023.2 (winter) to compare the difference; 4. TNF-α ELISA KIT was used to compare the proinflammatory cytokines in two groups 5. 4HNE (4-Hydroxynonenal )ELISA KIT was used to compare the lipid reactive oxygen species level in two groups 6. Quantitative reverse transcription PCR (Polymerase Chain Reaction) was used to compare messenger ribonucleic acid (mRNA) expression of the Nrf2-dependent ferroptosis pathway (Nrf2, SLC7A11, GPX4) Detailed Methods protocol 1\. PM2.5 level source: the PM2.5 levels were recorded via the data from the Ministry of Ecology and Environment of the People's Republic of China (air.cnemc.cn:18007) 2. The criteria of enrolled participants were as follows:Inclusion: living in this city for more than 3 years; no exposure to any chemistry pollution before; Exclusion: significant changes in biomarkers (TNF-α, Nrf2, SLC7A11, GPX4) at the beginning; neurological disorders; endocrine diseases; cancer 3. Sample collection: At the beginning and the end of this study, the enrolled participant will come to the hospital to collect peripheral Blood (Northern Jiangsu and Xuzhou center, respectively), and the blood samples will be collected into EDTA (ethyleneDiamine tetraacetic acid) vacutainer tubes and then divided into leukocytes and plasma for further experiments 4. TNF-α ELISA KIT: Plasma TNF-α concentrations were detected by the competitive ELISA method 5. 4HNE(4-Hydroxynonenal )ELISA KIT : Plasma 4HNE concentrations were detected by the competitive ELISA method 6. primer sequence: h-GPX4 forward: 5'-GAGGCAAGACCGAAGTAAACTAC-3' h-GPX4 reverse: 5'-CCGAACTGGTTACACGGGAA-3' h-SLC7A11 forward: 5'-TCTCCAAAGGAGGTTACCTGC-3' h-SLC7A11 reverse: 5'-AGACTCCCCTCAGTAAAGTGAC-3' h-Nrf2 forward 5'-ATAGCTGAGCCCAGTATC-3' h-Nrf2 reverse 5'- CATGCACGTGAGTGCTCT-3' h-GAPDH forward: 5'-GGAGCGAGATCCCTCCAAAAT-3' h-GAPDH reverse: 5'-GGCTGTTGTCATACTTCTCATGG-3'

Conditions

Timeline

Start date
2022-12-01
Primary completion
2023-02-25
Completion
2023-03-01
First posted
2023-03-03
Last updated
2023-03-03

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05753332. Inclusion in this directory is not an endorsement.